Protagenic Therapeutics

(NASDAQ) PTIX

Current PriceN/A

Market CapN/A

Since IPO (2025)-94%

5 Year-99%

1 Year-65%

1 Month+2%

Protagenic Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$5.16M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 11, 2026

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 11, 2026

PTIX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Protagenic Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Barrett Evans

Website

www.protagenic.com

Headquarters

New York City, NY 10010, US

PTIX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

Return on Capital

Return on Assets

-2%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$37.72K

Operating Income

-$5.83M

EBITDA

-$8.02M

Operating Cash Flow

-$4.14M

Capital Expenditure

-$3.00

Free Cash Flow

-$4.14M

Cash & ST Invst.

$2.21M

Total Debt

$3.16M

Protagenic Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

+100.0%

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$2.21M

+242.3%

EBITDA

-$912.53K

+40.8%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$2.21M

+20.4%

Total Debt

$3.16M

N/A

Accounts Receivable

$41.52K

N/A

Inventory

$1.07K

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$3.16M

N/A

Return on Assets

-2.42%

N/A

Return on Invested Capital

1.24%

N/A

Free Cash Flow

-$410.43K

+49.9%

Operating Cash Flow

-$410.42K

+49.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SLRXSalarius Pharmaceuticals, Inc.

SLRXSalarius Pharmaceuticals, Inc.$0.84+29.23%

LIPOLipella Pharmaceuticals Inc.

LIPOLipella Pharmaceuticals Inc.$0.08+0.00%

ARTLArtelo Biosciences, Inc.

ARTLArtelo Biosciences, Inc.$1.36+3.03%

INDPIndaptus Therapeutics, Inc.

INDPIndaptus Therapeutics, Inc.$3.58+0.28%

SLXNSilexion Therapeutics Ltd.

SLXNSilexion Therapeutics Ltd.$3.13+1.29%

REVBRevelation Biosciences, Inc.

REVBRevelation Biosciences, Inc.$1.00-1.36%

CARMCarisma Therapeutics, Inc.

CARMCarisma Therapeutics, Inc.$0.01+7.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$160.95+0.19%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.52+0.02%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.46-0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.02-0.00%

Questions About PTIX

What is the current price of Protagenic Therapeutics?

Protagenic Therapeutics is trading at N/A per share.

What is the 52-week range for Protagenic Therapeutics?

Over the past 52 weeks, Protagenic Therapeutics has traded between N/A and N/A.

How much debt does Protagenic Therapeutics have?

As of the most recent reporting period, Protagenic Therapeutics reported total debt of $4.00M.

How much cash does Protagenic Therapeutics have on hand?

Protagenic Therapeutics reported $2.21M in cash and cash equivalents in its most recent financial results.

What is Protagenic Therapeutics’s dividend yield?

Protagenic Therapeutics does not currently have a dividend yield.

Protagenic Therapeutics

Protagenic Therapeutics Financials at a Glance

PTIX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Protagenic Therapeutics

PTIX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Protagenic Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PTIX

What is the current price of Protagenic Therapeutics?

What is the 52-week range for Protagenic Therapeutics?

How much debt does Protagenic Therapeutics have?

How much cash does Protagenic Therapeutics have on hand?

What is Protagenic Therapeutics’s dividend yield?

Premium Investing Services